Drug interactions of tipranavir, a new HIV protease inhibitor.
Tipranavir is one of the latest approved HIV protease inhibitors. This non-peptidic molecule is an strong inducer of cytochrome P450 and has to be co-administered with low doses ritonavir as pharmacokinetic booster to achieve effective antiviral activity in vivo. As expected, significant drug interactions may occur in patients treated with tipranavir/ritonavir, including diminished exposure to some antiretroviral agents. Although a few interactions can be managed with adequate drug dosing others preclude to use these medications in combination.
Pharmacokinetic Unit, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain.
Judit
J
Morello
Sonia
S
Rodriguez-Novoa
Inmaculada
I
Jimenez-Nacher
Vincent
V
Soriano
D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects* / Q000378:metabolism; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004790:Enzyme Induction / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D011753:Pyrones / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D019438:Ritonavir / Q000008:administration & dosage; D013449:Sulfonamides
D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D003577:Cytochrome P-450 Enzyme System; D019438:Ritonavir; C107201:tipranavir